Business Context and Reporting Period
Company: Phase III Medical, Inc. (Note: Metadata lists "Lisata Therapeutics," but the filing text identifies the registrant as Phase III Medical, Inc.)
Reporting Period: Quarterly Report (Form 10-Q) for the period ended June 30, 2005.
Business Model: The Company provides capital and consulting to healthcare and life sciences companies in exchange for revenue/royalty shares. It is also managing the "run-off" of its former internet-based extended warranty business. As of June 30, 2005, the Company has not received payments from its new healthcare investments.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2005 | Six Months Ended June 30, 2004 |
|---|---|---|
| Revenue | $19,983 | $34,415 |
| Gross Profit | $5,963 | $10,271 |
| Operating Loss | $(568,298) | $(794,340) |
| Net Loss | $(642,736) | $(948,386) |
| Cash Flow from Operations | $(332,608) | $(765,146) |
| Cash Flow from Financing | $305,000 | $559,237 |
| Cash and Equivalents (End of Period) | $260 | $1,750 |
| Total Current Liabilities | $1,627,703 | $1,288,050 |
| Accumulated Deficit | $(13,153,062) | $(12,510,326) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 42% year-over-year ($19,983 vs. $34,415) as the warranty business continues to run off with no new sales.
- Reduced Net Loss: Net loss improved by approximately 32% to $(642,736) from $(948,386). This improvement was primarily driven by the cessation of payments for the purchase of medical royalty streams (which were $480,000 in the prior period) and reduced interest expense.
- Increased Operating Expenses: Selling, general, and administrative (SG&A) expenses increased by approximately 77% to $574,261, driven by higher payroll, legal fees, and investor relations costs.
- Liquidity Crisis: Cash balances plummeted to $260 from $27,868 at year-end 2004. The Company relies entirely on financing activities (issuance of stock and notes) to fund operations.
Outlook, Risks, and Contingencies
- Going Concern Doubt: Management explicitly states that the Company has limited financial resources to pay current expenses and liabilities, raising substantial doubt about its ability to continue as a going concern.
- Financing Needs: The Company commenced a private placement on June 28, 2005, seeking $500,000 to $2,000,000 in Senior Secured Convertible Notes and Warrants. As of August 11, 2005, no funds had been closed or remitted.
- Debt Obligations: Significant debt is due or extended, including $170,000 in notes due August 31, 2005, and $504,722 in accrued dividends on Series A Preferred Stock.
- Contractual Commitments: The Company has a commitment to pay Parallel Solutions, Inc. (PSI) up to an additional $205,940 for bioshielding technology development.
- Stock Issuances: Significant dilution occurred through stock issuances for services, debt conversion, and executive compensation (e.g., 3,000,000 shares approved for CEO in July 2005).
Investor Verification Checklist
- Cash Runway: Verify if the private placement of convertible notes has closed, as the Company has only $260 in cash and substantial debt due in August 2005.
- Debt Default Risk: Confirm the status of the $170,000 in notes due August 31, 2005, and the $504,722 in accrued preferred dividends.
- Revenue Generation: Assess the likelihood of the new healthcare royalty model generating revenue, given zero revenue from this segment to date.
- Dilution Impact: Review the impact of recent and approved stock issuances (including the 3,000,000 shares to the CEO and 8,000,000 options granted) on existing shareholder value.
- Going Concern Status: Evaluate the Company's ability to meet payroll and legal obligations without immediate equity or debt financing.